In vivo effector functions of high-affinity mouse IgG receptor FcγRI in disease and therapy models

Journal of Autoimmunity

Volumn 80, Issue , 2017, Pages 95-102

  Gillis, Caitlin M ^a,b,c   Zenatti, Priscila P ^a,b   Mancardi, David A ^a,b   Beutier, Héloïse ^a,b,c   Fiette, Laurence ^a   Macdonald, Lynn E ^d   Murphy, Andrew J ^d   Celli, Susanna ^a,e   Bousso, Philippe ^a,e   Jönsson, Friederike ^a,b   Bruhns, Pierre ^a,b  

^a INSTITUT PASTEUR   (France)

^b INSERM   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d REGENERON PHARMACEUTICALS INC   (United States)

^e INSTITUT PASTEUR   (France)

Author keywords

Fc receptors; IgG induced pathologies; Immunotherapy; Mouse models

Indexed keywords

CD20 ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN RECEPTOR; BLOCKING ANTIBODY; FC RECEPTOR; FCGR1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; BLOOD SAMPLING; CANCER IMMUNOTHERAPY; CELL POPULATION; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE SEVERITY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOCOMPETENT CELL; IN VIVO STUDY; LEUKOCYTE COUNT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SYSTEMIC ANAPHYLAXIS; THROMBOCYTOPENIA; ANIMAL; ANTIBODY AFFINITY; B LYMPHOCYTE; C57BL MOUSE; DISEASE MODEL; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; KNOCKOUT MOUSE; LIVER RESECTION; METABOLISM; PROCEDURES; SPLENECTOMY;

ANIMALS; ANTIBODIES, BLOCKING; ANTIBODY AFFINITY; B-LYMPHOCYTES; DISEASE MODELS, ANIMAL; HEPATECTOMY; HUMANS; IMMUNOTHERAPY; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, IGG; SPLENECTOMY;

EID: 84994464119     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2016.09.009     Document Type: Article

References (41)

1. [1] Bruhns, P., Properties of mouse and human IgG receptors and their contribution to disease models. Blood 119 (2012), 5640–5649.
2. [2] Bruhns, P., Jonsson, F., Mouse and human FcR effector functions. Immunol. Rev. 268 (2015), 25–51.
3. [3] Nimmerjahn, F., Ravetch, J.V., Fcgamma receptors: old friends and new family members. Immunity 24 (2006), 19–28.
4. [4] van der Poel, C.E., Spaapen, R.M., van de Winkel, J.G., Leusen, J.H., Functional characteristics of the high affinity IgG receptor, FcgammaRI. J. Immunol. 186 (2011), 2699–2704.
5. [5] Gillis, C., Gouel-Cheron, A., Jonsson, F., Bruhns, P., Contribution of human FcgammaRs to disease with evidence from human polymorphisms and transgenic animal studies. Front. Immunol., 5, 2014, 254.
6. [6] Bogdanovich, S., Kim, Y., Mizutani, T., Yasuma, R., Tudisco, L., Cicatiello, V., et al. Human IgG1 antibodies suppress angiogenesis in a target-independent manner. Signal Transduct. Target Ther., 1, 2016.
7. [7] Bevaart, L., Van Ojik, H.H., Sun, A.W., Sulahian, T.H., Leusen, J.H., Weiner, G.J., et al. CpG oligodeoxynucleotides enhance FcgammaRI-mediated cross presentation by dendritic cells. Int. Immunol. 16 (2004), 1091–1098.
8. [8] Mancardi, D.A., Albanesi, M., Jonsson, F., Iannascoli, B., Van Rooijen, N., Kang, X., et al. The high-affinity human IgG receptor FcgammaRI (CD64) promotes IgG-mediated inflammation, anaphylaxis, and antitumor immunotherapy. Blood 121 (2013), 1563–1573.
9. [9] van Vugt, M.J., Heijnen, A.F., Capel, P.J., Park, S.Y., Ra, C., Saito, T., et al. FcR gamma-chain is essential for both surface expression and function of human Fc gamma RI (CD64) in vivo. Blood 87 (1996), 3593–3599.
10. [10] McIntosh, R.S., Shi, J., Jennings, R.M., Chappel, J.C., de Koning-Ward, T.F., Smith, T., et al. The importance of human FcgammaRI in mediating protection to malaria. PLoS Pathog., 3, 2007, e72.
11. [11] Ioan-Facsinay, A., de Kimpe, S.J., Hellwig, S.M., van Lent, P.L., Hofhuis, F.M., van Ojik, H.H., et al. Fc gamma RI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity 16 (2002), 391–402.
12. [12] van Lent, P.L., Nabbe, K., Blom, A.B., Holthuysen, A.E., Sloetjes, A., van de Putte, L.B., et al. Role of activatory Fc gamma RI and Fc gamma RIII and inhibitory Fc gamma RII in inflammation and cartilage destruction during experimental antigen-induced arthritis. Am. J. Pathol. 159 (2001), 2309–2320.
13. [13] Barnes, N., Gavin, A.L., Tan, P.S., Mottram, P., Koentgen, F., Hogarth, P.M., FcgammaRI-deficient mice show multiple alterations to inflammatory and immune responses. Immunity 16 (2002), 379–389.
14. [14] Baumann, U., Kohl, J., Tschernig, T., Schwerter-Strumpf, K., Verbeek, J.S., Schmidt, R.E., et al. A codominant role of Fc gamma RI/III and C5aR in the reverse Arthus reaction. J. Immunol. 164 (2000), 1065–1070.
15. [15] Bevaart, L., Jansen, M.J., van Vugt, M.J., Verbeek, J.S., van de Winkel, J.G., Leusen, J.H., The high-affinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma. Cancer Res. 66 (2006), 1261–1264.
16. [16] Otten, M.A., van der Bij, G.J., Verbeek, S.J., Nimmerjahn, F., Ravetch, J.V., Beelen, R.H., et al. Experimental antibody therapy of liver metastases reveals functional redundancy between Fc gammaRI and Fc gammaRIV. J. Immunol. 181 (2008), 6829–6836.
17. [17] Albanesi, M., Mancardi, D.A., Macdonald, L.E., Iannascoli, B., Zitvogel, L., Murphy, A.J., et al. Cutting edge: FcgammaRIII (CD16) and FcgammaRI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma. J. Immunol. 189 (2012), 5513–5517.
18. [18] Minard-Colin, V., Xiu, Y., Poe, J.C., Horikawa, M., Magro, C.M., Hamaguchi, Y., et al. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Blood 112 (2008), 1205–1213.
19. [19] Nimmerjahn, F., Bruhns, P., Horiuchi, K., Ravetch, J.V., Fc gamma RIV: a novel FcR with distinct IgG subclass specificity. Immunity 23 (2005), 41–51.
20. [20] Nimmerjahn, F., Lux, A., Albert, H., Woigk, M., Lehmann, C., Dudziak, D., et al. FcgammaRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 19396–19401.
21. [21] Tipton, T.R., Mockridge, C.I., French, R.R., Tutt, A.L., Cragg, M.S., Beers, S.A., Anti-mouse FcgammaRIV antibody 9E9 also blocks FcgammaRIII in vivo. Blood 126 (2015), 2643–2645.
22. [22] Mancardi, D.A., Iannascoli, B., Hoos, S., England, P., Daeron, M., Bruhns, P., FcgammaRIV is a mouse IgE receptor that resembles macrophage FcepsilonRI in humans and promotes IgE-induced lung inflammation. J. Clin. Investig. 118 (2008), 3738–3750.
23. [23] Jönsson, F., Mancardi, D.A., Kita, Y., Karasuyama, H., Iannascoli, B., Van Rooijen, N., et al. Mouse and human neutrophils induce anaphylaxis. J. Clin. Investig. 121 (2011), 1484–1496.
24. [24] Mancardi, D.A., Jonsson, F., Iannascoli, B., Khun, H., Van Rooijen, N., Huerre, M., et al. The murine high-affinity IgG receptor Fc(gamma)RIV is sufficient for autoantibody-induced arthritis. J. Immunol. 186 (2011), 1899–1903.
25. [25] Bruhns, P., Samuelsson, A., Pollard, J.W., Ravetch, J.V., Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 18 (2003), 573–581.
26. [26] Jönsson, F., Mancardi, D.A., Zhao, W., Kita, Y., Iannascoli, B., Khun, H., et al. Human FcgammaRIIA induces anaphylactic and allergic reactions. Blood 119 (2012), 2533–2544.
27. [27] Overdijk, M.B., Verploegen, S., Ortiz Buijsse, A., Vink, T., Leusen, J.H., Bleeker, W.K., et al. Crosstalk between human IgG isotypes and murine effector cells. J. Immunol. 189 (2012), 3430–3438.
28. [28] Gillis, C.M., Jönsson, F., Mancardi, D.A., Tu, N., Beutier, H., Van Rooijen, N., et al. Mechanisms of anaphylaxis in human low-affinity IgG receptor locus knock-in mice. In press J. Allergy Clin. Immunol., 2016, 10.1016/j.jaci.2016.06.058.
29. [29] Tan, P.S., Gavin, A.L., Barnes, N., Sears, D.W., Vremec, D., Shortman, K., et al. Unique monoclonal antibodies define expression of Fc gamma RI on macrophages and mast cell lines and demonstrate heterogeneity among subcutaneous and other dendritic cells. J. Immunol. 170 (2003), 2549–2556.
30. [30] Langlet, C., Tamoutounour, S., Henri, S., Luche, H., Ardouin, L., Gregoire, C., et al. CD64 expression distinguishes monocyte-derived and conventional dendritic cells and reveals their distinct role during intramuscular immunization. J. Immunol. 188 (2012), 1751–1760.
31. [31] Monach, P.A., Mathis, D., Benoist, C., The K/BxN arthritis model. (Chapter 15):Unit 15 Curr. Protoc. Immunol., 2008, 22.
32. [32] Singer II, Kawka, D.W., Bayne, E.K., Donatelli, S.A., Weidner, J.R., Williams, H.R., et al. VDIPEN, a metalloproteinase-generated neoepitope, is induced and immunolocalized in articular cartilage during inflammatory arthritis. J. Clin. Investig. 95 (1995), 2178–2186.
33. [33] Jonsson, F., Mancardi, D.A., Albanesi, M., Bruhns, P., Neutrophils in local and systemic antibody-dependent inflammatory and anaphylactic reactions. J. Leukoc. Biol. 94 (2013), 643–656.
34. [34] Beutier, H., Gillis, C.M., Iannascoli, B., Godon, M., England, P., Sibilano, R., et al. IgG subclasses determine pathways of anaphylaxis in mice. In press J. Allergy Clin. Immunol., 2016, 10.1016/j.jaci.2016.03.028.
35. [35] Baudino, L., Nimmerjahn, F., Azeredo da Silveira, S., Martinez-Soria, E., Saito, T., Carroll, M., et al. Differential contribution of three activating IgG Fc receptors (FcgammaRI, FcgammaRIII, and FcgammaRIV) to IgG2a- and IgG2b-induced autoimmune hemolytic anemia in mice. J. Immunol. 180 (2008), 1948–1953.
36. [36] Montalvao, F., Garcia, Z., Celli, S., Breart, B., Deguine, J., Van Rooijen, N., et al. The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging. J. Clin. Investig. 123 (2013), 5098–5103.
37. [37] Biburger, M., Aschermann, S., Schwab, I., Lux, A., Albert, H., Danzer, H., et al. Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo. Immunity 35 (2011), 932–944.
38. [38] Uchida, J., Hamaguchi, Y., Oliver, J.A., Ravetch, J.V., Poe, J.C., Haas, K.M., et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199 (2004), 1659–1669.
39. [39] Hamaguchi, Y., Xiu, Y., Komura, K., Nimmerjahn, F., Tedder, T.F., Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J. Exp. Med. 203 (2006), 743–753.
40. [40] Mittal, R., Sukumaran, S.K., Selvaraj, S.K., Wooster, D.G., Babu, M.M., Schreiber, A.D., et al. Fcgamma receptor I alpha chain (CD64) expression in macrophages is critical for the onset of meningitis by Escherichia coli K1. PLoS Pathog., 6, 2010, e1001203.
41. [41] Esser-von Bieren, J., Volpe, B., Kulagin, M., Sutherland, D.B., Guiet, R., Seitz, A., et al. Antibody-mediated trapping of helminth larvae requires CD11b and Fcgamma receptor I. J. Immunol. 194 (2015), 1154–1163.